22-LUN-130-MSD (MK-7339 -013-03): A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib (MK-7339), Compared to Conc

Grants and Contracts Details

StatusActive
Effective start/end date1/13/2310/25/24

Funding

  • Merck Sharp & Dohme Corporation: $154,974.00